Research programme: non-steroidal anti-inflammatory drugs - Angelini PharmaceuticalsAlternative Names: Nsaids new formulations - Angelini
Latest Information Update: 15 Jul 2016
At a glance
- Originator Angelini Pharmaceuticals
- Class Analgesics; Nonsteroidal anti-inflammatories
- Mechanism of Action Cyclooxygenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation; Pain
Most Recent Events
- 15 Jul 2016 Preclinical trials in Pain in Italy (unspecified route)
- 15 Jul 2016 Preclinical trials in Inflammation in Italy (unspecified route)